S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
S&P 500   4,541.82 (-0.17%)
DOW   35,665.22 (+0.17%)
QQQ   374.09 (-0.84%)
AAPL   149.17 (-0.21%)
MSFT   309.17 (-0.51%)
FB   323.07 (-5.50%)
GOOGL   2,742.95 (-3.34%)
TSLA   903.64 (+1.08%)
AMZN   3,355.70 (-2.31%)
NVDA   228.07 (+0.51%)
BABA   177.63 (+0.12%)
NIO   39.01 (-2.40%)
CGC   13.36 (-4.84%)
GE   103.91 (+0.74%)
AMD   119.76 (+0.36%)
MU   67.52 (-1.63%)
T   25.52 (-0.93%)
F   16.38 (-1.03%)
ACB   7.11 (-3.53%)
DIS   168.84 (-1.46%)
PFE   42.88 (+0.05%)
BA   212.87 (-0.69%)
AMC   36.29 (-7.52%)
CVE:TAK

Takeda Pharmaceutical Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume143,897 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Headlines

Global Plasma Protein Therapeutics Market (2021 to 2027) - Featuring Takeda Pharmaceutical, Bio Products Laboratory and CSL Behring Among Others
October 15, 2021 |  finance.yahoo.com
Worldwide Orphan Drugs Industry to 2027 - Featuring Jazz Pharmaceuticals, Merck & Co and Pfizer Among Others
October 7, 2021 |  finance.yahoo.com
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
October 7, 2021 |  msn.com
Takeda To Stop Phase 2 Studies Of Investigational Oral Orexin Agonist TAK-994
October 6, 2021 |  nasdaq.com
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 6, 2021 |  msn.com
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
October 6, 2021 |  finance.yahoo.com
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
October 6, 2021 |  markets.businessinsider.com
Japan Moderna Supplier Takeda Plans Its Second-Biggest Yen Bond
October 1, 2021 |  finance.yahoo.com
Takeda Pharma preparing to sell $1.8 bln in 10-year straight bonds - Nikkei
October 1, 2021 |  nasdaq.com
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
September 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Medicinal and Botanical Manufacturing
Sub-Industry
N/A
Sector
Manufacturing
Current Symbol
CVE:TAK
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.takugold.com
Phone
+1-604-6420115
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
N/A
Market Cap
N/A
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Takeda Pharmaceutical (CVE:TAK) Frequently Asked Questions

What stocks does MarketBeat like better than Takeda Pharmaceutical?

Wall Street analysts have given Takeda Pharmaceutical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Gilles Dessureau, Interim President
  • Gregory Donald Hayes, Interim Chief Financial Officer, Corporate Secretary
  • Peter Bures, Director
  • Dennis Gordon Fentie, Director
  • Janet Lee-Sheriff, Director
  • Lori Walton, Director
  • C.F. Wasser III, Director

Who are some of Takeda Pharmaceutical's key competitors?

Some companies that are related to Takeda Pharmaceutical include Tilray (TLRY), Theseus Pharmaceuticals (THRX), Advantis (ADVT), High Tide (HITI) and Novus Energy (NVS).
View all of TAK's competitors.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Pure Gold Mining (PGM), Valhi (VHI) and Fission Uranium (FCUUF).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TAK."

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 2,021 workers across the globe.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takugold.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 409 Granville St Suite 608, VANCOUVER, BC V6C 1T2, Canada.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 409 Granville St Suite 608, VANCOUVER, BC V6C 1T2, Canada. The company can be reached via phone at +1-604-6420115.


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.